Group 1 - Liu Pharmaceutical Group plans to repurchase shares worth between 100 million and 200 million yuan, with a maximum repurchase price of 25.70 yuan per share [1] - Dongshan Precision intends to invest up to 1 billion USD to build a high-end printed circuit board project to meet the long-term demand for high-end printed circuit boards in emerging scenarios such as AI [1] - Bomaike reported a net profit of 12.39 million yuan for the first half of the year, a year-on-year decline of 80.42% [2] Group 2 - Western Mining achieved a net profit of 1.869 billion yuan in the first half of the year, a year-on-year increase of 15% [2] - Fuliwang expects a net loss of approximately 17 million yuan for the first half of the year, a decrease of 137.12% compared to the same period last year [2] - Digital Certification anticipates a net loss of between 80 million and 96 million yuan for the first half of the year, compared to a loss of 29.25 million yuan in the same period last year [3] Group 3 - Shanghai Construction reported a net profit of 710 million yuan for the first half of the year, a year-on-year decrease of 14.04% [5] - Funneng Co. achieved a net profit of 1.337 billion yuan in the first half of the year, a year-on-year increase of 12.48% [6] - Tengda Construction's total contract amount for the first half of the year decreased by 17.55% year-on-year [7] Group 4 - Fudan Fuhua decided to terminate the public transfer of a 28% stake in a subsidiary due to the lack of a deposit from potential buyers [9] - Fulei Ant's subsidiary has decided to cease operations due to intense competition in the photovoltaic industry and ongoing losses [11] - Dongfang Ocean's subsidiary received a medical device registration certificate for a folic acid testing kit [14] Group 5 - Huayu Pharmaceutical's subsidiary received overseas listing approvals for several products [16] - Feima International received a performance commitment compensation of 437 million yuan from its controlling shareholder [16] - Guangshen Railway signed a cooperation agreement for the Guangzhou East Station renovation project with a total investment of approximately 16.66 billion yuan [16] Group 6 - Anhui Construction won the bid for the S68 Jingde to Jixi Expressway project with an estimated total investment of 5.7 billion yuan [18] - China Communications Construction Company signed new contracts worth 991.054 billion yuan in the first half of the year, a year-on-year increase of 3.14% [19] - Kehui Co. plans to use up to 70 million yuan of idle funds for cash management [22] Group 7 - Biological Shares' subsidiary received a clinical trial approval for a cat mRNA vaccine, the first of its kind in China [23] - Ruipu Biological received a clinical trial approval for a pig mRNA vaccine, which is the first economic animal mRNA vaccine in China [24] - Nanjing New Hundred's major assets were judicially frozen due to liquidity debt crisis faced by its controlling shareholder [27] Group 8 - Changshu Bank plans to merge three village banks and establish branches, pending shareholder approval [28] - Yong'an Pharmaceutical plans to reduce its holdings by up to 2.6323 million shares [29] - Zhujiang Co. received approval from the Shanghai Stock Exchange for a stock issuance to specific targets [31] Group 9 - Sanyangma's subsidiary signed a 120 million yuan procurement contract for sensor products [33] - Jintou City Development plans to purchase a villa property for approximately 7.1854 million yuan [35] - Yuanli Co. intends to acquire 100% of Tongsheng Co. through a combination of cash and stock issuance [36] Group 10 - Xin'an Century's controlling shareholder plans to reduce holdings by up to 2.22% of the company's shares [36] - Fute Technology plans to raise up to 528 million yuan through a private placement for various projects [36] - Helen Piano's actual controller is set to change, with stock resuming trading [37] Group 11 - Weiergao expects a net profit increase of 12.55% to 30.87% for the first half of the year [38] - Saiwei Microelectronics plans to transfer up to 18% of its shares through an agreement [40] - Yongli Co. intends to acquire a 22.75% stake in a subsidiary [42] Group 12 - ST Xiachuang plans to publicly transfer a 20% stake in Guangdong Yuweiji [43] - Dema Technology's shareholders plan to transfer 778.84 million shares through an inquiry [45] - Zhongshi Technology's shareholders plan to reduce holdings by up to 2.86% of the company's shares [46] Group 13 - Wufang Optoelectronics' controlling shareholder plans to reduce holdings by up to 0.93% of the company's shares [48] - Fusenmei's chairman has been detained, temporarily unable to fulfill his duties [49] - Reliable Co.'s shareholders plan to reduce holdings by a total of up to 2.63% of the company's shares [51] Group 14 - Gao Neng Environment plans to repurchase shares worth between 100 million and 150 million yuan [53]

Corporate Announcements - Sanfeng Intelligent's director Chen Wei has been placed under investigation, but the company's operations remain normal and unaffected [3] - Shanghai Pharmaceuticals plans to acquire a 10% stake in Shanghai Shihua Group Financial Company for 143 million yuan, increasing its ownership from 30% to 40% [4] - Western Gold intends to acquire 100% of Xinjiang Meisheng Mining for 1.655 billion yuan, with a premium of 1421.66% over book value; the target company is expected to commence production in the second half of 2025 [5] - Hengrui Medicine plans to acquire approximately 1.46% of Chengdu Shengdi Pharmaceutical from minority shareholders for 40.144 million yuan, increasing its stake to 97.37% [6] - Dongshan Precision has approved an investment of up to 1 billion USD for a high-end printed circuit board project to meet long-term demand in emerging markets [7] - ST Wanfang and Rebecca have both received notices from the China Securities Regulatory Commission regarding investigations into information disclosure violations, but their operations remain normal [8][9] Financial Performance - China Duty Free Group reported a net profit of 2.6 billion yuan for the first half of 2025, a decrease of 20.81% year-on-year, with total revenue of 28.151 billion yuan, down 9.96% [13] - Digital Certification expects a loss of 80 to 96 million yuan for the first half of 2025, compared to a loss of 29.25 million yuan in the same period last year [14] - Western Mining reported a net profit of 1.869 billion yuan for the first half of 2025, an increase of 15% year-on-year, with total revenue of 31.619 billion yuan, up 27% [15] Major Contracts - ST Dongyi signed new orders worth 215 million yuan in the second quarter for its decoration business, with total uncompleted contracts amounting to 383 million yuan [17] - Guangshen Railway signed a cooperation agreement for the Guangzhou East Station renovation project, with a total investment of approximately 16.66 billion yuan [18] Shareholder Actions - Huajin Technology's employee stock ownership platform plans to reduce its stake by up to 4% within three months [20] - Liuyuan Group intends to repurchase shares worth between 100 million and 200 million yuan, with a maximum repurchase price of 25.7 yuan per share [22]

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-053 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于以集中竞价交易方式回购股份方案的公告 ● 回购股份价格：不超过人民币 25.70 元/股（含），该价格不高于董事会审 议通过回购方案决议前 30 个交易日公司股票交易均价的 150%。 ● 回购股份方式：集中竞价交易方式。 ● 回购股份期限：自董事会审议通过本次回购方案之日起不超过 12 个月。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 广西柳药集团股份有限公司（以下简称"公司"）基于对未来发展前景的信心 和对公司长期价值的高度认可，为推动公司股票价值的合理回归，稳定投资者预 期，增强市场信心，维护公司和全体股东的利益，并进一步落实"提质增效重回 报"行动方案，公司拟以集中竞价交易方式回购公司发行的部分人民币普通股 A 股股份。主要内容如下： ● 回购股份金额：不低于人民币 10,000 ...

柳药集团（603368）公告，公司拟以集中竞价交易方式回购公司发行的部分人民币普通股A股股份。回 购金额不低于人民币1亿元(含)，不超过人民币2亿元(含)，资金来源为公司自有资金和自筹资金。回购 股份价格不超过人民币25.7元/股(含)，预计回购股份数量约为389.11万股~778.21万股，占公司总股本的 0.98%~1.96%。回购股份用途为拟在未来适宜时机用于实施股权激励及/或员工持股计划；若公司未能在 本次股份回购完成后3年内实施上述用途，则未使用的已回购股份将履行相关程序予以注销。 ...

关于 广西柳药集团股份有限公司 限制性股票回购注销实施的 法律意见书 深圳市福田区深南大道 4011 号香港中旅大厦 21-26 层 邮政编码（Postcode）：518048 电话（Tel.）：0086-755-83025555 传真（Fax.）：0086-755-83025068 网址（Website）：www.huashanglawyer.com 法律意见书 目 录 法律意见书 广东华商律师事务所 关于广西柳药集团股份有限公司 限制性股票回购注销实施的 法律意见书 致：广西柳药集团股份有限公司 广东华商律师事务所（以下简称"本所"）接受贵公司的委托，担任贵公司 实施 2023 年限制性股票激励计划的专项法律顾问。根据《中华人民共和国公司 法》《中华人民共和国证券法》《上市公司股权激励管理办法》等有关法律、法 规及规范性文件和《广西柳药集团股份有限公司章程》的规定，就贵公司回购注 销 2023 年限制性股票激励计划限制性股票相关事项出具《广东华商律师事务所 关于广西柳药集团股份有限公司 2023 年限制性股票激励计划限制性股票回购注 销实施的法律意见书》。 法律意见书 | 释 义 | | | --- | ...

证券代码：603368 证券简称：柳药集团 公告编号：2025-052 转债代码：113563 转债简称：柳药转债 广西柳药集团股份有限公司 关于限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 回购注销原因：广西柳药集团股份有限公司（以下简称"公司"）2023 年限制性股票激励计划（以下简称"本激励计划"）中的 1 名预留授予激励对象 因个人原因离职而不再具备激励资格，公司决定对其持有的已获授但尚未解除限 售的 3,000 股限制性股票予以回购注销；因公司决定终止实施本激励计划，公司 需回购注销除上述 1 名离职激励对象以外的 181 名激励对象已获授但尚未解除限 售的 1,692,050 股限制性股票。 ● 本次注销股份的有关情况： 回购股份数量 注销股份数量 注销日期 一、本次限制性股票回购注销的决策与信息披露 公司于 2025 年 4 月 28 日召开第五届董事会第二十六次会议和第五届监事会 第二十次会议，并于 2025 年 5 月 19 日召开 2025 年第一次临 ...

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-052 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 回购注销原因：广西柳药集团股份有限公司（以下简称"公司"）2023 年限制性股票激励计划（以下简称"本激励计划"）中的 1 名预留授予激励对象 因个人原因离职而不再具备激励资格，公司决定对其持有的已获授但尚未解除限 售的 3,000 股限制性股票予以回购注销；因公司决定终止实施本激励计划，公司 需回购注销除上述1名离职激励对象以外的181名激励对象已获授但尚未解除限 售的 1,692,050 股限制性股票。 ● 本次注销股份的有关情况： | 回购股份数量 | 注销股份数量 | | 注销日期 | | | | | --- | --- | --- | --- | --- | --- | --- | | 股 1,695, ...

关于 广西柳药集团股份有限公司 2023 年限制性股票激励计划 限制性股票回购注销实施的 法律意见书 法律意见书 深圳市福田区深南大道 4011 号香港中旅大厦 21-26 层 邮政编码（Postcode）：518048 21-26/F, HKCTS Tower, 4011 Shennan Road, Futian District, Shenzhen, P. R. China 电话（Tel.）：0086-755-83025555 传真（Fax.）：0086-755-83025068 网址（Website）：www.huashanglawyer.com | 释 | 义 iii | | --- | --- | | 第一节 | 法律意见书引言 i | | 第二节 | 法律意见书正文 1 | | | 一、本次回购注销的批准和授权 1 | | | 二、本次回购注销的原因、数量、回购价格和资金来源等情况 7 | | | 三、本次回购注销的实施进展 10 | | | 四、结论性意见 11 | 在《广东华商律师事务所关于广西柳药集团股份有限公司 2023 年限制性股 票激励计划限制性股票回购注销实施的法律意见书》中，除上下 ...

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-051 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于公司及下属控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | 广西柳药集团股份有限公司（简称"公司"） 万元 | | --- | --- | --- | --- | | | 本次担保金额 | 500.00 | | | 担保 对象一 | 实际为其提供的担保余额 | 15,530.83 | 万元（含本次） | | | 是否在前期预计额度内 | 是 | □否 不适用：_________ | | | 本次担保是否有反担保 | □是 | 否 不适用：_________ | | 担保 | 被担保人名称 | | 广西南宁柳药药业有限公司（简称"南宁柳药"） | | | 本次担保金额 | 13,714.17 | 万元 | | 对象二 ...

Summary of Key Points Core Viewpoint - The announcement provides an update on the conversion status of the "Liuyao Convertible Bonds" issued by Guangxi Liuyao Group Co., Ltd., highlighting the low conversion rate and the significant amount of unconverted bonds. Group 1: Convertible Bond Issuance Overview - The company issued 8,022,000 convertible bonds on January 16, 2020, with a total value of RMB 800.22 million and a maturity period of 6 years [1][2] - The initial conversion price was set at RMB 34.94 per share, which was later adjusted to RMB 21.18 per share due to a rights distribution plan [2] Group 2: Conversion Status - As of June 30, 2025, a total of RMB 321,000 worth of "Liuyao Convertible Bonds" has been converted into shares, representing 0.0400% of the total bonds issued [1][2] - The total number of shares converted is 13,180, which accounts for 0.0036% of the total shares before conversion [1][2] - The remaining unconverted bonds amount to RMB 801,879,000, which constitutes 99.9600% of the total bonds issued [1][2] Group 3: Share Capital Changes - The total number of shares before the conversion on March 31, 2025, was 398,863,861, which increased to 398,863,908 after the conversion on June 30, 2025 [3]